AK5

Across TCGA pan-cancer cohorts, AK5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AK5 data layer compared with 19 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AK5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AK5 expression acts as an unfavorable survival marker, although some lineages such as LUSC and SKCM show a favorable association.

LUAD, HNSC, and STAD are the cancer types where AK5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.149	0.674	<.001	31	view →
HNSC	OS	Median	All	0.259	0.605	.031	12	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	All	0.766	0.389	.020	5	view →
SKCM	DFS	Median	II,III,IV	0.859	0.665	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AK5–LUAD (OS)

Open the LUAD breakdown →